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Plasma degradome affected by variable 
storage of human blood
Maria Kaisar1,2,4, Leon F. A. van Dullemen3†, Marie‑Laëtitia Thézénas4†, M. Zeeshan Akhtar1, Honglei Huang1,4, 
Sandrine Rendel1, Philip D. Charles4, Roman Fischer4, Rutger J. Ploeg1,2‡ and Benedikt M. Kessler4*‡ 
Abstract 
Background: The successful application of—omics technologies in the discovery of novel biomarkers and targets 
of therapeutic interventions is facilitated by large collections of well curated clinical samples stored in bio banks. 
Mining the plasma proteome holds promise to improve our understanding of disease mechanisms and may repre‑
sent a source of biomarkers. However, a major confounding factor for defining disease‑specific proteomic signatures 
in plasma is the variation in handling and processing of clinical samples leading to protein degradation. To address 
this, we defined a plasma proteolytic signature (degradome) reflecting pre‑analytical variability in blood samples that 
remained at ambient temperature for different time periods after collection and prior to processing.
Methods: We obtained EDTA blood samples from five healthy volunteers (n = 5), and blood tubes remained at ambi‑
ent temperature for 30 min, 8, 24 and 48 h prior to centrifugation and isolation of plasma. Naturally occurred peptides 
derived from plasma samples were compared by label‑free quantitative LC–MS/MS. To profile protein degradation, 
we analysed pooled plasma samples at T = 30 min and 48 h using PROTOMAP analysis. The proteolytic pattern of 
selected protein candidates was further validated by immunoblotting.
Results: A total of 820 plasma proteins were surveyed by PROTOMAP, and for 4 % of these, marked degradation was 
observed. We show distinct proteolysis patterns for talin‑1, coagulation factor XI, complement protein C1r, C3, C4 and 
thrombospondin, and several proteins including S100A8, A9, annexin A1, profiling‑1 and platelet glycoprotein V are 
enriched after 48 h blood storage at ambient temperature. In particular, thrombospondin protein levels increased 
after 8 h and proteolytic fragments appeared after 24 h storage time.
Conclusions: The overall impact of blood storage at ambient temperature for variable times on the plasma pro‑
teome and degradome is relatively minor, but in some cases can cause a potential bias in identifying and assigning 
relevant proteomic markers. The observed effects on the plasma proteome and degradome are predominantly trig‑
gered by limited leucocyte and platelet cell activation due to blood handling and storage. The baseline plasma degra‑
dome signature presented here can help filtering candidate protein markers relevant for clinical biomarker studies.
Keywords: Pre analytical variability, Ambient temperature, Plasma proteome, PROTOMAP, Mass spectrometry, 
Biobank, QUOD
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Background
The successful application of—omics technologies in 
medical research for discovering disease-specific molec-
ular processes is facilitated by access to large collections 
of well curated clinical samples available for analysis. 
Biobanks as a source of biological samples with associ-
ated clinical and demographic data are essential for the 
study of disease mechanisms and for the discovery of 
novel biomarkers and targets of therapeutic interven-
tions [1]. For many discovery studies, longitudinal blood, 
urine samples and organ biopsies are collected, processed 
and stored according to detailed standard operating pro-
tocols within hospitals. Often, guidelines suggest that 
blood samples should be transferred on dry ice to pre-
vent protein degradation [2, 3]. We recently established 
a large UK biobank, within the framework of NHS Blood 
and Transplant, collecting samples from 60 national wide 
sites in organ donation and transplantation (QUOD) 
[4]. The purpose of UK QUOD biobank is to provide a 
comprehensive collection of clinical samples, obtained 
during deceased donor organ management, for research 
on organ donation and transplantation. In developing 
the protocols for QUOD, we realised that there is a lack 
of a consensus in the collection, processing and storage 
protocols for blood, urine, other body fluids or tissue 
biopsies not only relevant for QUOD specifically, but 
also for other biobanks in general. For blood in particu-
lar, variables due to sample handling have been described 
[5] which may differ in the context of measuring specific 
clinical parameters such as vitamin E (alpha-tocopherol) 
[6] glucose [7], but also for immunoassays [8], blood 
based amyloid-beta assays [9], C-reactive protein CRP 
[10] or sCD40L [11]. Recently, proteomic technolo-
gies have been employed for the discovery of biomark-
ers and novel targets of interventions in diverse fields of 
medicine. In such studies, there are many variables that 
can influence the outcome of mass spectrometry based 
serum/plasma proteomics [12, 13]. Eliminating sample 
variability is particularly important to reduce false-pos-
itive discovery of potential biomarkers [14, 15]. Recom-
mendations for sample processing vary from immediate 
storage of blood on ice to storage and processing at ambi-
ent temperature. Lower temperatures reduce partial deg-
radation of plasma proteins but lead to an increase in 
proteins related to platelet activation and coagulation [16, 
17]. We reasoned that cooling samples may lead to unde-
sirable artefacts and more variability, thereby introducing 
a bias to the observed results. We are therefore favouring 
blood sample handling at ambient temperature for whole 
blood collection and previously showed that the plasma 
proteome is remarkable stable in AT following blood 
collection [18]. Protein degradation (degradome) or the 
peptidome (naturally occurring peptide fragments) has 
been assessed in plasma, in particular in the context of 
coagulation [19], and proteolytic fragments derived from 
fibrinogen alpha chain, apolipoprotein A-IV, A-I, comple-
ment C3 and alpha-1 antitrypsin can be readily detected, 
and they were reported to correlate with tumorigenesis 
but potentially confounded with clotting [15]. As keeping 
blood at ambient temperature does minimise platelet and 
complement activation and since these conditions are 
more applicable in a clinical setting, we set out to system-




We collected 40  ml blood from five healthy individuals 
in EDTA gel vacutainer plasma gel separator tubes (BD, 
Vacutainer® PPTTM Plastic tube with BD Pearlescent 
White HemogardTM Closure). Blood samples were col-
lected from healthy volunteers within Oxford University 
according to the research consent policy [20]. Blood was 
collected by peripheral venepuncture using a 20-gauge 
needle and was mixed with EDTA by gently inverting 
the EDTA tubes, followed by storage at ambient tem-
perature ~22  °C (AT) for 30 min, 8, 24, or 48 h (Fig. 1). 
For the purpose of this study, ambient temperature (AT) 
was defined as 22 ± 2 °C, and the protocols for prepara-
tion of all the samples were the same for each participant. 
Subsequently, plasma was prepared by centrifugation at 
1500×g for 15 min at 22 °C. Plasma supernatant was ali-
quoted and stored at −80  °C until further analysis. No 
haemolysis was observed in any of the blood samples 
before or after blood centrifugation or during the period 
of 48  h at ambient temperature. Plasma samples were 
immunodepleted of highly abundant proteins prior to 
further processing as described below.
Plasma depletion of highly abundant proteins
Antibody affinity-based depletion of high abundance 
proteins present in human plasma was conducted using 
an Agilent Human top 14 Multiple Affinity Removal Sys-
tem (MARS) coupled to an Ultimate 3000 HPLC system 
(Thermo Scientific) following manufacturer’s instruc-
tions. Briefly, 80  µl plasma aliquots were centrifuged 
at 10,000×g for 10  min, diluted four times in Buffer A 
(Agilent Technologies, UK) and separated on the MARS 
column according to the manufacturer’s instructions. 
Protein depletion followed a sequence of isocratic elu-
tion steps: 100 % buffer A for 20 min at 0.125 ml/min fol-
lowed by 0.7 ml/min for 2.5 min. Flow-through fractions 
containing the depleted plasma were collected between 
7.5 and 14.5 min of each sample run. Between runs, the 
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column was washed with buffer B (Agilent Technologies, 
UK) until the UV214nm trace was back to baseline. Each 
sample was injected four times to obtain sufficient quan-
tity of protein for further analysis.
Protein precipitation of individual plasma samples
Flow-through protein fractions of depleted plasma sam-
ples were precipitated with the addition of sodium deox-
ycholate to a final concentration of 125  µg/ml followed 
by 15 min incubation at 22  °C. Trichloroacetic acid was 
added to a final concentration of 6  %, followed by cen-
trifugation at 12,000×g at 4  °C for 30  min. Following 
centrifugation, sample supernatants containing natu-
rally occurring peptides were collected in new tubes for 
separate analyses. Protein precipitates were washed with 
ice-cold acetone, centrifuged at 12,000×g for further 
10 min and pellets resuspended in 50 µl of 6 M urea in 
100  mM Tris HCl (pH 7.8). Quantitation of each sam-
ple was performed by a BCA protein assay according 
to the manufacturer’s instructions (Thermo Scientific, 
BCA UK) and 80 Âµg of protein per sample was analysed 
(Fig. 1). Protein precipitates and naturally occurred pep-
tides were further processed and subjected to label-free 
semi-quantitative liquid chromatography tandem mass 
spectrometry (LC–MS/MS) and PROTOMAP analysis as 
described below.
Plasma proteome analysis
15  µg of precipitate protein material was used for 
each individual sample. Samples were reduced for 1 h 
by addition of 200  mM dithiothreitol (DTT) followed 
by alkylation with 200  mM iodoacetamide (IAA) for 
30 min. Trypsin digestion was performed overnight at 
37 °C with gentle mixing using a 1:50 (trypsin:protein) 
ratio. Samples were acidified with 1  % FA or TFA. 
Peptide digests were then desalted using Sep-Pak C18 
cartridges (Waters) and dried by Speed Vac centrifu-
gation. Pellets were resuspended in 30  µl of buffer A 
(98 % Milli-Q-H2O, 2 % acetonitrile, 0.1 % formic acid) 
and kept at −20  °C until analysis. Peptides were ana-
lysed in duplicates by nano ultra-high performance 
liquid chromatography tandem mass spectrometry 
(nUHPLC–MS/MS) using a Dionex Ultimate 3000 
UHPLC (C18 column with a 75 μm × 250 mm, 1.7 μm 
particle size, Thermo Scientific, Bremen, Germany) 
coupled to a Q Exactive tandem mass spectrometer 
(Thermo Scientific, Bremen, Germany) as described 
previously [21].
  Time whole blood samples remained         





     EDTA  Blood samples   
  Plasma samples   
Centrifugation
PROTOMAP 
   Tryptic  digests 
    LC-MS/MS   n=5 
   Naturally occurring peptides  
                LC-MS/MS   n=5 
    Pool 1 
 T=30min 
     n=5 
    Pool 2 
    T=48h 
      n=5 
T=30min T=8h T=24h T=48h 
          Profile of degradation events  Comparison of plasma proteomic signature  
Fig. 1 Experimental workflow. Four EDTA blood tubes were collected from five healthy volunteers (n = 5) and remained at ambient temperature 
for T = 30 min, 8, 24 or 48 h before centrifugation, processing and analysis by liquid chromatography tandem mass spectrometry (LC–MS/MS). 
Comparison of plasma proteomic signatures of individual samples by LC–MS/MS of tryptic (reflecting proteins) and naturally occurred peptides 
(peptidome) in blood performed at the indicated time points. Profiling of protein degradation (degradome) in plasma from pooled blood samples 
(n = 5) collected at 30 min and 48 h was performed and subsequently analysed using PROTOMAP
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Proteomic analysis of naturally occurred peptides 
in plasma
Naturally occurred plasma peptides present in supernatant 
fractions after protein precipitation were purified using 
Sep-Pak C18 cartridges according to the manufacturer’s 
instructions. In brief, solid phase cartridges were equili-
brated in 98  % Acetonitrile (ACN), 0.1  % Formic Acid 
(FA) and 2 % ACN, 0.1 % FA. Samples were then loaded 
onto the cartridge followed by washing with 2 % Acetoni-
trile (ACN), 0.1  % Formic Acid (FA) solution and subse-
quent peptide elution using 50 % ACN, 0.1 % FA. Peptide 
fractions were dried by vacuum centrifugation overnight. 
Pellets were resuspended in 20 µl of buffer A (98 % Milli-
Q-H2O, 2 % acetonitrile, 0.1 % formic acid) and analysed 
by nUHPLC–MS/MS in duplicates as described above.
Data analysis for plasma proteome
Raw MS data were processed using MSConvert v3.0.7529 
(ProteoWizard) and analysed using Progenesis QI for 
Proteomics (QIP) software v3.1.4003.30577 (Nonlinear 
Dynamics). MS/MS spectra were searched against the 
UniProt Homo Sapiens Reference proteome (retrieved 
15/10/2014) using Mascot v2.5.1 (Matrix Science) allow-
ing for a precursor mass tolerance of 10 ppm and a frag-
ment ion tolerance of 0.5 Da, Carbamidomethylation on 
Cysteines as fixed, and Deamidation (Glutamine) and 
Oxidation (Methionine) as variable modifications with 
a false discovery rate (FDR) of 1 %. Mascot results were 
imported into Progenesis QIP. Only proteins that were 
defined with at least 2 unique peptides were included 
in the protein data set for further analysis. Statistical 
comparison of protein abundance changes observed 
between the four time points of whole blood centrifuga-
tion (T = 30 min and T = 8, 24, and 48 h) was performed 
using a one-way ANOVA F-test within the Progenesis QI 
software (calling significant changes at p ≤ 0.05).
Data analysis for naturally occurred peptides in plasma
Sequence interpretation of MS/MS spectra of naturally 
occurred peptides was performed by the interrogation 
of UniProt Homo Sapiens database using PEAKS Online 
v7.5 (Bioinformatics Solutions Inc.) with an FDR of 1 % 
and imported into the Progenesis QI software for quan-
titation. Average normalised abundance values were 
obtained via quantile normalisation using the Progen-
esis IQ software. For proteins, precursor ion intensi-
ties of unique tryptic peptides matched to the protein 
sequence were used. Only proteins that were defined 
with at least two unique peptides were included in the 
protein data set for further analysis. For naturally occur-
ring peptides, individual precursor ion counts were used 
for quantitation and average normalised abundances 
obtained as described above. Statistical comparison of 
protein abundance changes observed between the four 
time points (n =  5 each) of whole blood centrifugation 
(T =  30  min and T =  8, 24, and 48  h) was performed 
using a one-way ANOVA F-test within the Progenesis QI 
software (calling significant changes at p ≤ 0.05).
PROTOMAP analysis
To profile protein degradation events occurring in whole 
blood exposed to AT for different times, we used a PRO-
TOMAP approach as described previously [22]. For this 
analysis, we created two plasma pools obtained from 
5 healthy individuals as described in Fig. 1. Pool 1 con-
tained plasma samples prepared from whole blood by 
centrifugation after 30  min following blood collection 
and Pool 2 contained plasma samples prepared 48 h after 
collection. After depletion of the most abundant plasma 
components (see above), 60  µg of protein per pool was 
reduced in standard Laemmli buffer with DTT, divided 
into two aliquots and separated by SDS–PAGE (NOVEX 
Invitrogen 4–12 % gradient, Thermo Scientific, Bremen, 
Germany). The gel was stained with Coomassie blue 
and each pooled sample lane was cut into 22 horizontal 
slices, generating 44 samples overall (Fig.  1). Each sam-
ple was subjected to in-solution trypsin digestion as 
described previously [23]. In brief, gel pieces were de-
stained in a solution of 1 ml 50 % methanol, 5 % acetic 
acid in Milli-Q-H2O solution until transparent, then 
dehydrated using 200 µl ACN for 5 min. Proteins in gel 
pieces were reduced by addition of 30 µl of 10 mM dithi-
othreitol (DTT) for 30  min followed by alkylation with 
30  µl of 50  mM iodoacetamide (IAA) for 30  min. Gel 
pieces were dehydrated with 200  µl ACN, resuspended 
in 30  µl 100  mM ammonium bi-carbonate containing 
20  ng/µl trypsin and incubated overnight at 37  °C with 
gentle mixing. Peptide digests were extracted from the 
gel matrix using 50 µl extraction buffer I (50 % ACN, 5 % 
FA) followed by 50 µl extraction buffer II (85 % ACN, 5 % 
FA), collected and dried by vacuum centrifugation. Pel-
lets were resuspended in 30 µl of buffer A (98 % Milli-Q-
H2O, 2 % acetonitrile, 0.1 % formic acid) and analysed by 
nUHPLC–MS/MS using a Thermo LTQ Q Exactive tan-
dem mass spectrometer as described previously [24].
Analysis of PROTOMAP derived mass spectrometry data
The PROTOMAP integrates the protein migration patterns 
on SDS–PAGE electrophoresis with peptide sequence cov-
erage and spectral counts acquired by LC–MS/MS analysis, 
and the results are visualised as peptographs (Fig. 2) [22]. 
In brief, raw data was converted to Mascot generic files 
using msconvert [25], searched with Mascot and further 
analysed as described by Niessen et  al, [19]. To expound, 
MS/MS spectra data were searched using Mascot v2.5.1 
against the UniProt Homo sapiens Reference proteome 
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(retrieved 15/10/2014). The Mascot results were exported 
as DTASelect at an FDR threshold of 1  %, and analysed 
using the PROTOMAP perl scripts obtained from http://
www.scripps.edu/cravatt/protomap/. Peptographs consist 
of two panels and combine information on 1-D gel migra-
tion of protein fragments, protein sequence coverage and 
spectral counts of protein fragments per gel band. The left 
panel shows the protein sequence coverage from N to C 
terminus in each band. Peptide sequences represented in 
red and blue were identified in the 30 min and 48 h pools, 
respectively, while peptide fragments represented in pur-
ple were common to both pooled samples in the same 
band. The right panel shows the relative quantitation using 
spectral counts for each protein between the two pools. 
The red bars represent the “parent proteins” which are the 
intact proteins that were identified in the plasma samples 
prepared after centrifugation at T  =  30  min while blue 
bars represent the spectral counts of proteins in the sam-
ples centrifuged T  =  48  h following collection. Protein 
degradation is defined by fragments with spectral counts 
detected in lower molecular weight bands as compared to 
the expected size of the “parent protein”.
Western blot validation
Depleted plasma samples containing 20 µg of protein were 
denatured at 95  °C for 5  min in Laemmli buffer, loaded 
onto and separated by 4–12  % pre-cast SDS-PAGE gels 
(Bio-Rad, USA), followed by immunoblotting onto PVDF 
membranes (Merck Millipore, USA) using standard pro-
tocols. Membranes were incubated overnight at 4 °C with 
monoclonal rabbit anti-C4B (1  µg/ml, Abcam Ab168358) 
or goat polyclonal anti thrombospondin-1 (1.2 µg/ml, R&D 
systems AF3074). 1:5000 dilution of Dye-800-conjugated 
anti-goat or -rabbit IgG (Li-Cor, Nebraska, USA) were used 
Fig. 2 Effect of blood storage on plasma proteome and peptidome signatures. Plasma protein levels stay essentially constant upon blood stored at 
ambient temperature for different times. a Abundance levels of all proteins (represented by their corresponding tryptic peptides) identified at the 
indicated times (Additional file 1: Table S1). b Abundance levels of proteins showing > twofold change (ANOVA p < 0.05). c Abundance levels of 140 
naturally occurred peptides (peptdidome) in plasma observed at the indicated times. d Abundance levels of naturally occurring peptides in plasma 
showing > twofold change (ANOVA p < 0.05)
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as secondary antibodies for detection. Bands were detected 
using an Odyssey CLx system (Li-Cor Nebraska, USA).
Results
Plasma proteome and peptidome signatures of stored 
blood
To establish how the plasma proteome and degradation 
profile was affected by leaving whole blood at ambient 
temperature for a period of 30 min up to 48 h, we ana-
lysed plasma collected from 5 individuals whose blood 
was stored at ambient temperature for 30 min, 8, 24 and 
48 h, respectively (Fig. 1). Interestingly, LC–MS/MS anal-
ysis revealed no obvious trend of change in the majority 
of protein levels with respect to time (at least 2 unique 
peptides and > 95 %confidence in protein identification) 
(Fig.  2a, b, Additional file  1: Table S1 for the list of all 
identified proteins). Next, we established how the plasma 
degradome profile was affected by storage via the analy-
sis of naturally occurring peptides in plasma collected 
from five individuals whose blood was stored at ambi-
ent temperature for 30  min, 8, 24 and 48  h (Figs.  1, 2). 
Interestingly, LC–MS/MS analysis revealed only minor 
changes in peptides assigned to 140 plasma proteins 
(Fig.  2c). There was a significant increase in proteolytic 
peptides derived from nine proteins after 48  h. These 
included complement C4 and the cytoskeletal proteins 
vinculin, importin and filamin (Fig. 2d).
PROTOMAP reveals minimal storage related degradation 
of plasma proteins
To further map the proteolytic fragments of plasma 
proteins in whole blood stored at ambient temperature 
in greater detail, we applied a PROTOMAP approach. 
Pooled plasma samples (n  =  5) derived from the blood 
storage conditions of 30 min and 48 h were compared and 
analysed (Fig. 3). The PROTOMAP method compares two 
conditions (control vs experimental), hence the require-
ment for pooling [22]. PROTOMAP analysis identified 
overall 820 proteins and notably only 52 proteins revealed 
changes between the T =  30  min and T =  48 h plasma 
pools. Shortlisted proteins (visualised as peptographs) 
showed patterns of degradation or enrichment, and 
25  
M 30 m    48 h 
LC- MS/MS 
n= 22 
T=30 min T= 48h 
n= 22 
In-gel digestion 
• 44 MS/MS  files 
• Mascot search 
• DTASelect 
• Peptographs 
Protein separation                        
   via SDS Gel 
Analysis of each sample pool per lane 
1
22 
Spectral counts              Peptide coverage 
N-terminus  C 
T=30m 
T= 48h 











Fig. 3 PROTOMAP workflow. The 30 min (Pool 1, n = 5) and 48 h samples (Pool 2, n = 5) were separated by 1‑D SDS‑PAGE and proteins visualised 
by Coomassie blue staining. The gel was subsequently divided into 22 bands per lane (representing one condition each). Each pool per band was 
cut to create n = 22 pieces per condition, proteins were subjected to in‑solution trypsin digestion and analysed by LC‑MS/MS. Raw MS data was 
analysed by PROTOMAP bioinformatics to generate peptographs [22]
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their selection was based on either (i) increased spectral 
counts of fragments that had migrated at a lower molec-
ular weight region than the intact protein or (ii) being 
enriched or uniquely identified at 48 h (Figs. 4, S1). From 
the 52 proteins, 20 were enriched in plasma, 22 showed 
breakdown products indicating likely proteolysis and for 
10 proteins, we observed a combination of enrichment 
and degradation. Examples of peptographs are shown 
in Figs.  4, Additional file  1: S1 and S2. Peptographs of 
S100A8, S100A9, annexin A1, platelet glycoprotein 4 and 
profilin-1 demonstrate enrichment of these proteins at 
48 h as were identified in the expected molecular weight 
at 10, 13, 38, 15 and 75 kDa, respectively, for each protein 
(Fig.  4a). Talin-1 showed increased fragmentation of the 
Protein S100 A9  
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  60 








  40 
  60 Profilin-1  
Platelet glycoprotein V  10 20 
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Complement C3 20 40 
  60 
  80 
Fig. 4 PROTOMAP indicates plasma protein enrichment or degradation as a function of variable blood storage. a Protein S100 A9, S100 A8, annexin 
A1, profiling‑1 and platelet glycoprotein V levels are enriched after 48 h of blood storage (blue bars) as compared to 30 min (red bars). b Prolonged 
blood storage provokes partial degradation of talin‑1, coagulation factor XI, complement C1r, C3 and actin as exemplified by their corresponding 
peptographs (blue bars—30 min; red bars—48 h blood storage at ambient temperature)
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intact protein (>250 kDa) over time with breakdown inter-
mediates observed at 140 kDa, 30–40 kDa and 15–22 kDa 
at 48 h. Coagulation factor XI (CFXI) and complement C3 
show no protein enrichment but the appearance of degra-
dation fragments at ~8 kDa for CXI and C3 (Fig. 4b). We 
also observed degradation profiles for fibrinogen alpha 
chain, serpin A3/A4, EMC1, ceruloplasmin, plasminogen-
like protein A, PON1, ITIH1, fibronectin, apolipoprotein 
B-100 (Additional file 1: Figure S1) and complement C2/
C5 (Additional file  1: Figure S2). In all these cases, the 
appearance of lower molecular weight protein fragments 
increases after blood storage for 48  h. Protein degrada-
tion profiled by PROTOMAP was validated by western 
blotting for thrombospondin 1 (TSP-1) and complement 
C4B. TSP-1 increased gradually to a maximum fold of 1.4 
in the 48 h condition as compared to 30 min, consistent 
with LC–MS/MS analysis (Fig. 5a). PROTOMAP showed 
an increase of the intact protein (~150  kDa) and the 
appearance of protein fragments within the 80–150 kDa 
range and an N-terminal proteolytic fragment of ~25 kDa 
(Fig.  5b). Western blot validation of plasma TSP-1 for 
all four conditions indicated a gradual increase in TSP-1 
protein levels correlating with the time of blood stor-
age at ambient temperature (Fig.  5b). The predicted size 
of intact TSP-1 is 133  kDa. However, PROTOMAP and 
immunoblotting revealed a storage time-dependent accu-
mulation of protein species in the range of 120–150 kDa, 
most likely due to increased cellular secretion and pro-
teolytic processing. C4B complement protein was identi-
fied in plasma at ~200 kDa with predominant fragments 
at 100 and 75 kDa corresponding to α chain and β chain, 
respectively [26]. Interestingly, as indicated by the pep-
tograph analysis, fragments observed in the range of 












































Fig. 5 Prolonged blood storage affects TSP‑1 protein levels and degradation. a Gradual increase of TSP‑1 protein levels as indicated by label‑free 
quantitative mass spectrometry analysis of tryptic peptides, indicating a 1.3‑fold change after 48 h of blood storage (p < 0.001). b TSP‑1 protein 
degradation patterns as observed by the PROTOMAP peptograph (red bars—30 min; blue bars—48 h) and confirmed by western blot analysis at 
the indicated times. The stars indicated in the PROTOMAP peptograph correspond to the bands in the 120–150 kDa region observed in the western 
blot, suggesting an increase in protein levels as well as partial degradation
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when compared to 30 min control samples, possibly as a 
result of secretion of newly expressed protein and subse-
quent enzymatic activity of the complement cascade that 
continues to occur during whole blood storage. Consist-
ent with this, we observed an increased abundance of 
lower molecular weight fragments and the generation of 
novel fragments below the 50 kDa mark over time (Fig. 6). 
Notably, a cluster of fragments between 35–40  kDa 
potentially corresponding to the C4d complement protein 
[26] was gradually increased with storage time. The C4B 
peptograph indicates the generation of two more C4B 
derived fragments at ~30  kDa that might correspond to 
C4 γ chain and an additional fragment at ~15  kDa [26], 
which were not detected by immunoblotting. PROTO-
MAP analysis also detected similar proteolytic degrada-
tion patterns of other complement proteins such as C1r, 
C2, C3 and C5 (Figs. 4, Additional file 1: S1). Combined, 
these results indicate partial proteolytic processing of a 
small sub-fraction of members of the complement cas-
cade upon blood storage at ambient temperature.
Discussion
Blood is the commonest clinical sample collected in 
biobanks. We embarked on this study to optimise the qual-
ity of clinical samples whilst establishing a UK Biobank in 
organ donation and transplantation (QUOD) collecting 
biomaterial from more than 60 hospital sites including 
out-of-hours and in week-ends [4]. Despite a general ten-
dency in bio-banking to store whole blood in hypothermic 
temperatures of around 4  °C prior to sample processing, 
we favoured whole blood samples to remain at ambient 
temperature prior to plasma preparation. Our ration-
ale was to minimize platelet and leucocyte activation and 
the subsequent release of cytosolic proteins and enzymes 
that could constitute a potential source of bias [12]. Pre-
viously, we assessed how the plasma proteome is altered 
while whole blood stored in AT and can introduce a bias 
on selection of candidate proteins in biomarker discovery 
studies. Remarkably, under these conditions, less than 5 % 
of the identified 430 proteins were found to be altered [18].
The limited impact of ambient temperature in plasma 
proteome dynamics is consistent with the study by Agui-
lar-Mahecha and colleagues reporting minimal variability 
on medium to high abundant plasma proteins when whole 
blood remained at ambient temperature for up to 6  h as 
opposed to when stored and processed at 4 °C [27]. Also, 
no benefit in protein stability was found when blood tubes 
containing proteinase inhibitors were used for whole blood 
remaining at ambient temperature up to 6  h. Similarly, 
when we analysed naturally occurring peptides in plasma 
by LC–MS/MS, we only identified fragments from a small 
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Fig. 6 Minimal proteolysis of complement C4B upon blood storage. Blood sample pools centrifuged after 30 min and 48 h of storage at ambient 
temperature were analysed by PROTOMAP (red bars—30 min; blue bars—48 h) and anti‑complement C4B western blotting. The 40 kDa fragment 
highlighted with a star (*) was increased as shown by the PROTOMAP peptograph, corresponding to a degradation intermediate also detected by 
western blotting. This fragment corresponds to the C4d component. Two more fragments of lower MW were increased in the PROTOMAP pepto‑
graph, corresponding to ~18 and ~30 kDa
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Proteolysis is an intrinsic homeostatic phenomenon in 
blood, and for the consideration of proteolytic protein 
fragments to be potential biomarkers [28], we investigated 
the degree of plasma proteolysis due to collection and 
storage conditions. The plasma peptidome (derived from 
protein degradation) has been a source of novel biomark-
ers for human diseases including transplantation [29–32]. 
We used a global proteolytic topography and migration 
analysis platform (PROTOMAP) to assess plasma pro-
teolysis. Two extreme conditions, 30 min and 48 h, were 
selected to demonstrate the full effect of proteolysis, 
reflecting blood specimens collected in the clinic and 
remaining at ambient temperature over prolonged times 
or weekends prior to diagnostic analysis. Next to provid-
ing insights into proteolysis dynamics, SDS-PAGE based 
fractionation prior to LC–MS/MS analysis extended the 
number of plasma protein identification to 820. For 20 
proteins, we observed enrichment and the appearance of 
protein isoforms that were uniquely identified in the 48 h 
pool, and 22 proteins exerted a clear proteolysis profile. 
Thrombospondin-1 (TSP-1) was identified in both, sin-
gle LC–MS/MS and PROTOMAP analysis (Fig. 5a, b). A 
gradual increase in TSP-1 levels was observed between 
30  min, 8, 24 and 48  h and also confirmed by immuno-
blotting (Fig.  5). TSP-1, a 450  kDa matricellular protein, 
is one of the main constituents of alpha granules released 
from platelets following activation. Upon release, TSP-1 
undergoes proteolysis to generate several fragments in the 
140-, 75-, 50- and 25 kDa range [33]. Interestingly, some 
of these fragments appear to overlap with degradation 
intermediates of TSP1 that have anti-angiogenic proper-
ties [34]. PROTOMAP analysis also revealed an increase 
in a 150  kDa fragment with additional fragments in the 
range of 50–150 kDa. Notably, a 28 kDa N-terminal frag-
ment was found to be moderately enriched in the 48  h 
condition (Fig.  5a). This N-terminal domain may be a 
heparin binding domain that derives from serine-depend-
ent proteolysis within the platelet α granules [33–36]. This 
heparin binding fragment subsequently migrates to the 
platelet membrane to interact with the actin cytoskeleton 
and fibrin to stabilise platelet aggregates during platelet 
activation. It is currently unknown whether the release of 
this fragment was the result of degranulation due a low 
degree of platelet activation or whether it has been shed in 
plasma from platelet membranes. Changes in circulating 
levels of TSP-1 fragments have been considered as poten-
tial biomarkers of tumour cell metastasis, inflammation, 
haemostasis and thrombosis [37–40]. Pre-analytical vari-
ability of TSP-1 as described here can provide a baseline 
for more accurate diagnostic detection in plasma samples.
PROTOMAP also detected proteolytic fragments of 
the complement proteins C1r, C3, C4B and C5 (Fig.  6, 
Additional file 1: S1). Activation of platelets, even to a low 
degree, can activate and propagate the complement sys-
tem [41]. Similarly, the circulation of complement frag-
ments in plasma can trigger platelet activation. Potential 
triggers of platelet activation can be particles that are 
released or shed from white cells such as neutrophils or 
simply from the sheer stress to blood extracted from the 
vascular system during collection.
In summary, our study revealed remarkably few 
changes in plasma proteome dynamics with some dis-
tinct cases of proteins undergoing proteolytic degrada-
tion which affects their usefulness as disease biomarkers. 
More generally, blood sample storage at ambient temper-
ature appears suitable for maintaining high quality in the 
clinical context, in particular at highly unconventional 
hours of collection occurring in many hospital sites.
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